The antibody was purified by affinity chromatography, and conjugated with PE/Cy7 under optimal conditions. The solution is free of unconjugated PE/Cy7 and unconjugated antibody.
Storage & Handling:
The antibody solution should be stored undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining, the suggested use of this reagent is 20 µl per million cells or 20 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Application References:
1. Kishimoto, T., et al., Eds. 1997. Leucocyte Typing VI. Garland Publishing, Inc. London. 2. Peyron, P., et al., 2000. J. Immunol. 165:5186.
Human peripheral blood lymphocytes stained with JS11 PE/Cy7
Description:
CD55 is a 60-70 kD glycosylphosphatidylinositol (GPI)-anchored single chain glycoprotein also known as decay-accelerating factor (DAF). It is expressed on hematopoietic cells including erythrocytes and many non-hematopoietic cells. CD55 accelerates the dissociation of the components of the C3-convertases (namely C2a from C4b in the C4bC2a complex, a C3-convertase of the classical pathway, and factor Bb from the C3bBb complex, a C3-convertase of the alternative pathway) to protect cells from inappropriate damage caused by autologous complement. CD55 has been reported to reduce the efficiency of NK cell lysis and induce signal transduction in T cells. CD55 has also been shown to interact with CD97 and bind to Coxsackie and Echovirus.
Other Names:
DAF (Decay Accelerating Factor)
Structure:
GPI-achored regulator of complement activation (RCA), type I membrane glycoprotein, 60-70 kD
Distribution:
Hematopoietic cells including erythrocytes and many non-hematopoietic cells
Function:
Protects against inappropriate complement activation and cell damage, induces signal transduction, reduces the efficiency of NK cell lysis
Ligand Receptor:
C3b, C4b, CD97, Coxsackie viruses
Antigen References:
1. Schlossman, S., et al., Eds. 1995. Leucocyte Typing V. Oxford University Press. New York. 2. Hamann, J., et al., 1996. J. Exp. Med. 184: 1185. 3. Fujita, T., et al., 1987. J. Exp. Med. 166: 1221
*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering/). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.
